Ethylene Market Growth Till 2023

The global ethylene market is driven by growth in the use of polyethylene mainly for consumables; ethylene glycol/oxide for polyethylene terephthalate (PET) resins for PET fiber, bottles and other packaging; and ethylene dichloride for PVC plastic uses in construction and pipe. Polyethylene, the largest ethylene derivative, accounts for majority of the global ethylene consumption. Markets of polyethylene include film, packaging, containers and articles for home and light industrial use.

Ethylene is a colorless flammable gas with a musky odor. It is the simplest alkene and unsaturated hydrocarbon after acetylene. It is extensively used in agriculture as a plant hormone to ripen fruits; it is also used in the chemical industry to produce ethyl benzene, polyethylene, ethylene dichloride, and ethylene oxide among others. The ethylene production methods include steam cracking of paraffinic hydrocarbons or by separation from refinery gas. Industrial reactions of ethylene include alkylation, halogenation, polymerization, oxidation, hydro halogenation and others.

The production of textile fibers is growing significantly, especially in Asia-Pacific. In addition, producers of ethylene oxide have already been able to profit from the worldwide growing substitution of glass by PET bottles and containers. Furthermore, ethylene is used as a welding gas and as an anesthetic agent.

On the basis of applications of ethylene, the global ethylene market has been  segmented into high density polyethylene (HDPE),  low-density polyethylene (LDPE) and linear low density polyethylene (LLDPE), and intermediates of petrochemicals, mainly used for the production of plastics. The most important of these are ethylene dichloride and ethylbenzene and ethylene oxide.

As ethylene is combustible and carcinogenic, stringent regulations on the use of ethylene are expected to hamper the ethylene market. In addition, volatility in the feedstock cost along with rising competition within industry players also obstructs the growth of global ethylene market.

Some of the major competitors of the global ethylene market are Equistar Chemicals, BASF SE, LP, ExxonMobil Corporation, Chevron Phillips Chemical Company, The Dow Chemical Company, Formosa Plastics Corporation, U.S.A., INEOS, Sasol Ltd, Shell Chemical LP and Westlake Chemical Corporation among others.

News Courtesy : P&S Market Research

 

Advertisements

Spinal Muscular Atrophy Therapeutics – Pipeline Analysis, Clinical Trials & Results, 2017

Spinal Muscular Atrophy Therapeutics Pipeline Analysis

The study analyzed that the therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. Spinal muscular atrophy is defined as the inherited genetic disease that is characterized by a failure of nerve cells called motor neurons. Motor neurons are responsible to accept the nerve impulses transmitted from the brain to the spinal cord and transmit the impulses to the muscle with the help of peripheral nerves. The loss of motor neurons leads to muscle weakness in muscles that are closest to the trunk of the body such as back, hips and shoulders.

Imago Pharmaceuticals, Inc. is using nucleic acid therapeutics technology platform for the treatment of spinal muscular atrophy. Nucleic acid therapeutics technology includes large and innovative class of drugs that can modulate the function of target ribonucleic acid, or RNA, to ultimately affect the production of disease-associated proteins. Nucleic acid therapeutics comprise of complex mixtures of various chemical entities known as stereoisomers. Some stereoisomers in these mixtures have therapeutic effects, while others are less beneficial or contribute to undesirable side effects. Uncontrolled stereoisomer drug mixtures can lead to suboptimal efficacy and increased risk and safety concerns.

Some of the other key players developing drugs for the treatment of spinal muscular atrophy include Cytokinetics, Inc., F. Hoffman La-Roche Ltd, WAVE Life Sciences Ltd. and others.

News Courtesy: P&S Market Research

Post-Operative Pain Therapeutics – Pipeline Analysis, Clinical Trials & Results, 2017

Post-Operative Pain Therapeutics Pipeline

The post-operative pain therapeutics pipeline comprises approximately 39 drug candidates in different stages of development. Post-operative pain is one of the most common problem experienced by a person after any surgery. The intensity of pain can vary from acute to chronic depending upon the time it lasts. It starts when pain receptors activate an electrical signal that travels to the spinal cord. The spinal cord then transmits the signal to the brain. It involves the interaction of various chemicals, known as neurotransmitters, in the body, which together act to produce the sensation of pain in a person.

Innocoll Holdings plc is using CollaRx technology platform for the development of INL-001 for the treatment of post-operative pain. The CollaRx technology platform produces a lyophilized porous matrix of purified collagen that can be implanted at the time of surgery or applied topically to chronic or acute traumatic wounds. The CollaRx matrices are biodegradable and bio-resorbable. The in vivo release of drugs incorporated into the CollaRx matrix takes place via a combination of dissolution, diffusion and the interactive characteristics of the active drug and the formulation that can be modified to affect controlled release.

The research also found that various companies are developing their drug candidates as small molecule in the post-operative pain therapeutics pipeline.

Some of the key players developing drugs for post-operative pain include DURECT Corporation, Elite Pharmaceuticals, Inc., Cara Therapeutics, Inc. and others.

News Courtesy : P&S Market Research

Silica Aerogel materials Market use eco-friendly raw materials To Witness 31.1% CAGR During 2016 – 2022

Aerogel is an inimitable open-pore polymer foam, manufactured from either inorganic or organic predecessors. Aerogel is conventionally manufactured by means of sol-gel chemistry, which initiates with liquid state and forming tiny sol particles. These particles are interconnected with each other to form a semi-solid gel. Solid aerogel is formed by displacing solvent from the wet gel through air without breaking down the subtle gel structure. Aerogel has a nano-sized structure that comprises both particles and pores, which are smaller than the wavelength of visible light. Aerogel possesses optical, acoustic, thermal and optical properties, due to its nano-structure.

The global silica aerogel market is witnessing significant growth due to superior thermal insulation and lighter alternative, environment-friendly material and a large base of end-use applications. Additionally, silica aerogel is a potential substitute for conventional insulation materials and its use in fabrication of apparel for low temperature weather further boosted the demand for silica aerogel. The enhancement of thermal insulation systems are aimed towards reducing primary energy consumption. Silica aerogel is a potential substitute for conventional insulation materials such as mineral wool, fiberglass, polyurethane foam, polystyrene foam and cellulose. Silica aerogel, with low thermal conductivity (0.015 watts per meter kelvin), they offer extraordinary characteristics compared to conventional thermal insulation materials.

Among the various applications, the oil and gas segment has been globally the largest application area of silica aerogel, both in terms of value and volume. The challenges faced by oil and gas companies in the developing fields in harsh climatic conditions, such as deep/ultra-deep waters, oil sands and arctic environments, continue to increase. Thus, the focus has shifted on choosing an efficient and superior insulation system, which could meet environment landscape and regulations. Silica aerogel products are available in different forms to meet the wide variety of requirements of the oil and gas industry.

The key companies operating in the global silica aerogel market include BASF SE, The Dow Chemical Company, Cabot Corporation, Aspen Aerogels, Inc., Aerogel Technologies, LLC, JIOS Aerogel Corporation, Svenska Aerogel Holding AB, MAERO TECH SDN BHD, and Ocellus Inc.

News Courtesy :  P&S Market Research

Ulcerative Colitis has a Promising Pipeline with approximately 89 Drug Candidates

ulcerative colitis Pipeline AnalysisThe ulcerative colitis pipeline analysis report covers approximately 89 drug candidates in different stages of development.

Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators.

The research found that different companies are engaged in the collaboration for ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation collaborated for the development of Lycera Corp. drug candidate for the treatment of ulcerative colitis. Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retained full control of its research and development programs.

The novel technologies are being used for ulcerative colitis drug candidates. Protalix Ltd. is using ProCellEx technology platform for their drug candidates. ProCellEx technology platform overcomes the weaknesses by offering significant production, regulatory and cost benefits.

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.

News Courtesy: P&S Market Research

 

Novel Therapies for the Treatment of Age-related Macular Degeneration Treatment Drives the Overall Pipeline Growth

Age-related macular degeneration Therapeutic

The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.

Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.

There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.

Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.

News Courtesy: P&S Market Research

Friedreich’s Ataxia Therapeutics Pipeline to Develop More Drugs Being Derived from Natural Sources in the Future

Friedreich's Ataxia Therapeutics PipelineThe study analyzed that the Friedreich’s ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function.

According to the research findings, most of the drug candidates in Friedreich’s ataxia therapeutics pipeline are being developed to be administered by oral route.

Catabasis Pharmaceuticals, Inc. received Kyle Bryant Translational Research award from the FARA for the evaluation of their drug candidate, which is being developed for the treatment of Friedreich’s ataxia.

The research also found that various companies are in the process of developing the drug candidates using natural sources for the treatment of Friedreich’s ataxia therapeutics pipeline. Cardero Therapeutics, Inc. is in the process of developing a drug candidate as a sterol using natural source, for the treatment of Friedreich’s ataxia.

Some of the key players developing drugs for the treatment of Friedreich’s ataxia include Cardero Therapeutics, Inc., Edison Pharmaceuticals, Inc., Retrotope, Inc. and others.

News Courtesy: P&S Market Research

Cyclin-Dependent Kinase Inhibitors Therapeutics Pipeline Analysis 2017

Cyclin-Dependent Kinase Inhibitors Therapeutics

The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.

According to the research findings, most of the drug candidates of CDK inhibitors therapeutics pipeline are being developed to be administered by oral route.

USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the development and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.

Eli Lilly and Company and Boehringer Ingelheim GmbH entered into a collaboration for clinical studies of their drug candidates in combination, in patients diagnosed with HR+, HER2-metastatic breast cancer.

Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.

News Courtesy: P&S Market Research

Synovial Sarcoma Exhibits Emerging Pipeline with 22 Drug Candidates

Synovial Sarcoma Therapeutics Pipeline

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

The combination of novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

News Courtesy: P&S Market Research

Post-Traumatic Stress Disorder Exhibits Emerging Pipeline with 23 Drug Candidates

Post-Traumatic Stress DisorderThe study analysed that the PTSD pipeline comprises of 23 drug candidates in different stages of development. PTSD is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.

Many patents have been received during the development of drug candidates for the treatment of PTSD. In May 2017, Tonix reported the issuance of patent 9 636 408 by the United States Patent and Trademark Office titled “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the composition and manufacture of its proprietary sublingual formulation of very low dose cyclobenzaprine.

Significant growth in the therapeutic pipeline of PTSD is attributed to increasing collaboration between educational institutes, associations and pharma companies. Funds from the non-profit organizations have also been supporting the pipeline growth of PTSD therapeutics.

Some of the key players developing drugs for the treatment of PTSD include India Globalization Capital, Inc., Therapade Technologies LLC, Axim Biotechnologies, Inc. and others.

News Courtesy: P&S Market Research